课题基金 / 基金详情

Multiplexed analysis of exosomes in cancer nano therapy

Multiplexed analysis of exosomes in cancer nano therapy
癌症纳米疗法中外泌体的多重分析
批准号:
9487955
负责人:
RALPH WEISSLEDER, MD, PHD
金额:
$38.9万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-06-15 至 2021-05-31

项目摘要

项目成果

RALPH WEISSLEDER, MD, PHD的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
 DESCRIPTION (provided by applicant): Detection of reliable markers of therapy response and drug resistance remains a major clinical challenge in ovarian cancer. This is particularly true for a series of nanotherapeutics entering the clinical arena. One little explored opportunity lies in the analysis of exosomes, 50-200 nm sized vesicles continuously shed into the circulation. Importantly such tumor derived exosomes are abundant (1011 vesicles/ml of peripheral blood in cancer patients), are fairly stable over time and contain proteins reflective of those found in parent tumors. A current major challenge and opportunity is the development of methods for rapidly determining the abundance and composition of cMVs from clinical samples. We have recently developed a highly sensitive, nanotechnology-based, point-of-care diagnostic method termed nPLEX (nano Plasmonic Exosome) which comprises periodic nanohole arrays fabricated in an opaque gold film for transmission plasmon imaging (Nat Biotechnol 2014;32, 490-5). We have shown that i) such analyses are exquisitely sensitive, ii) allow profiling of dozens of proteins on and inside exosomes thus allowing cell of origin studies and iii) that nPLEX analysis allows sophisticated therapy assessment. The goal of this application is to advance the nPLEX technology by i) expanding it to allow parallel profiling of protein and RNA, ii) validating it as a therapeutic read-out of nanoparticle therapeutics in mouse models and in the clinic. We hypothesize that the approach will be more sensitive and comprehensive in exosomal analysis than is currently possible and allow treatment evaluation. The proposed integrated profiling method has the potential to transform nano therapeutic trials, cancer research and clinical practice. It will enable objective therapeutic read-outs, events that occur before conventional clinical metrics. It will facilitate extensive profiling of exosome in paucicellular clinical specimens, significantly reduce costs, and can be easily combined with other downstream analyses.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Bioorthogonal probe development for highly parallel in vivo imaging
  • 批准号:
    10596786
  • 项目类别:
  • 资助金额:
    $41.58万
  • 财政年份:
    2023
  • 负责人:
    RALPH WEISSLEDER, MD, PHD
  • 依托单位:
Temporal analysis of the GBM tumor microenvironment during myeloid cell activating therapy
  • 批准号:
    10704328
  • 项目类别:
  • 资助金额:
    $57.73万
  • 财政年份:
    2023
  • 负责人:
    RALPH WEISSLEDER, MD, PHD
  • 依托单位:
Ultrasenstive vesicle analysis in precancerous pancreatic neoplasm (IPMN)
  • 批准号:
    10615899
  • 项目类别:
  • 资助金额:
    $37.66万
  • 财政年份:
    2020
  • 负责人:
    RALPH WEISSLEDER, MD, PHD
  • 依托单位:
Ultrasenstive vesicle analysis in precancerous pancreatic neoplasm (IPMN)
  • 批准号:
    10403494
  • 项目类别:
  • 资助金额:
    $37.66万
  • 财政年份:
    2020
  • 负责人:
    RALPH WEISSLEDER, MD, PHD
  • 依托单位:
海外基金